Ajanta Pharma Limited (NSE:AJANTPHARM)
India · Delayed Price · Currency is INR | Market Cap | 382.68B +13.7% |
| Revenue (ttm) | 56.25B +21.0% |
| Net Income | 10.56B +14.7% |
| EPS | 84.51 +14.9% |
| Shares Out | 124.89M |
| PE Ratio | 36.26 |
| Forward PE | 31.19 |
| Dividend | 28.00 (0.92%) |
| Ex-Dividend Date | Nov 10, 2025 |
| Volume | 97,203 |
| Average Volume | 116,913 |
| Open | 3,045.00 |
| Previous Close | 3,035.00 |
| Day's Range | 2,987.30 - 3,090.00 |
| 52-Week Range | 2,329.90 - 3,228.00 |
| Beta | 0.20 |
| RSI | 65.09 |
| Earnings Date | May 5, 2026 |
About Ajanta Pharma
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, and pain management. The company operates in India, Africa, Asia, the United States, and intern... [Read more]
Financial Performance
In fiscal year 2026, Ajanta Pharma's revenue was 56.25 billion, an increase of 21.02% compared to the previous year's 46.48 billion. Earnings were 10.56 billion, an increase of 14.73%.
Financial StatementsNews
Q4 2026 Ajanta Pharma Ltd Earnings Call Transcript
Q4 2026 Ajanta Pharma Ltd Earnings Call Transcript
Pharma sector stocks rises today, May 6: Wockhardt jumps 7.16%, Ajanta Pharma surges 3.56%, Lupin up 1.60%
Indian pharmaceutical stocks traded higher in the early session on May 6, 2026. The Nifty Pharma index stood at 23,732.2, up 0.7%. The broader market also showed modest gains, with…
Ajanta Pharma Transcript: Q4 25/26
Revenue and profit saw double-digit growth in FY 2026, with strong performance across India, Africa, and U.S. segments. High teens revenue growth and 27% EBITDA margin are guided for FY 2027, factoring in higher costs and investments.
Ajanta Pharma announces re-appointment of auditors for FY 2026-27
Ajanta Pharma has announced the re-appointment of its internal, cost, and tax auditors for the financial year 2026-27. The decision was approved at the company's board meeting held on 5th…
Ajanta Pharma grants 1,45,000 stock options and cancels 850 under ESOP plan
Ajanta Pharma has announced the grant of 1,45,000 stock options under its Share Based Incentive Plan 2019. Each option covers one share, with an exercise period of three months from…
Ajanta Pharma Q4 Results: Revenue jumps 21.5% YoY to Rs 1,421.64 crore, net profit up 18.4%
Ajanta Pharma reported a strong performance for the fourth quarter of FY26, with healthy year-on-year growth across revenue and profitability, supported by steady operational momentum. Revenue from op...
Ajanta Pharma receives five observations from US FDA after facility inspection
Ajanta Pharma has announced that the US Food and Drug Administration (FDA) concluded an inspection at its manufacturing facility in Paithan, Maharashtra. The inspection, which took place from 13th Apr...
Pharma sector stocks today, April 21: Wockhardt surge 2.08%, Natco Pharma down 1.86%, Ajanta Pharma up 1.10%
The Indian pharma sector opened on a mixed note on April 21, 2026 (as of 9:43 AM). The S&P BSE Healthcare Index stood at 43,475.50, up 0.23%, while the NIFTY…
Pharma sector stocks today, April 16: Ajanta Pharma down 1.53%, Glenmark Pharma falls 1.23%, Lupin drops 1.08%
The S&P BSE Healthcare index is marginally in the red at -0.10% in early trade, while broader markets (Sensex +0.52%, Nifty 50 +0.39%) are positive. Most losses in the pharma…
Pharma sector stocks fall today, April 13: Biocon falls 2.35%, Cipla down 1.66%, Ajanta Pharma gains 0.77%
Pharmaceutical sector stocks traded mostly lower in early trade on Monday, April 13, 2026, with most counters under pressure. The S&P BSE Healthcare Index declined 0.88% to 42,246.47, while the…
Pharma sector stocks today, March 23: Alembic Pharma down 2.24%, Ajanta Pharma falls 1.85%, Glenmark Pharma falls 1.98%
The pharmaceutical sector in India experienced a downturn on March 23, 2026, as reflected in early morning trading data from BSE and NSE around 9:29-9:30 AM IST. Most listed pharma…
Pharma sector stocks today, March 17: Emcure Pharma surge 2.42%, Ajanta Pharma up 2.14%, Strides Pharma down 2.22%
The Indian pharmaceutical sector showed mixed performance on March 17, 2026, during early trading hours. The data reflects prices as of approximately 9:34 AM IST, with the S&P BSE HEALTHCARE…
Pharma sector stocks today, March 13: Laurus Labs down 2.56%, Ajanta Pharma falls 1.88%, Granules India drops 2.14%
The Indian pharmaceutical sector showed a downward trend in early trading on March 13, 2026, aligning with broader market weakness. The S&P BSE Healthcare Index stood at 43,441.0, down 0.6%…
Pharma sector stocks down today, March 2: Morepen Lab falls 3.24%, Ajanta Pharma drops 2.32%, Natco Pharma down 2.26%
The Indian pharmaceutical sector experienced a sharp decline on March 2, 2026, with many stocks trading lower in early sessions....
Ajanta Pharma Ltd (BOM:532331) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and ...
Ajanta Pharma Ltd (BOM:532331) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion Plans
Q3 2026 Ajanta Pharma Ltd Earnings Call Transcript
Q3 2026 Ajanta Pharma Ltd Earnings Call Transcript
Ajanta Pharma Transcript: Q3 25/26
Q3 FY26 revenue rose 20% YoY, led by strong India and U.S. generics growth, with robust margins and double-digit profit gains. Expansion in sales force, new product launches, and a Biocon partnership for GLP-1s support future growth, while guidance remains positive.
Pharma sector stocks today, Jan 30: Aurobindo Pharma jumps 3%, Ajanta Pharma up 2%, Natco Pharma rises 2%
The Indian pharma sector stocks showed mixed performance on January 30, 2026, as of approximately 10:31 AM IST. The sector...
India’s Ajanta Pharma eyes Irish manufacturing base
Indian speciality pharmaceutical firm Ajanta Pharma is understood to be eyeing a manufacturing operation in Ireland.
Ajanta Pharma shares jump over 4% after signing in-licensing agreement with Biocon
Shares of Ajanta Pharma Ltd. moved over 4% higher in early trade after the company announced a strategic in-licensing agreement...
Biocon signs out-licensing deal with Ajanta Pharma to market Semaglutide in overseas markets
Biocon Limited has announced the signing of an out-licensing agreement with Ajanta Pharma Ltd for the marketing of its vertically...
Bharti Airtel, Titan & more: Top stocks on brokers' radar today
Analysts are bullish on Bharti Airtel and Titan, citing strong quarterly results and positive outlooks. Ambuja Cements shows robust EBITDA, while Ajanta Pharma beats estimates with strong internationa...
Ajanta Pharma Ltd (BOM:532331) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amidst ...
Ajanta Pharma Ltd (BOM:532331) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Forex Challenges
Q2 2026 Ajanta Pharma Ltd Earnings Call Transcript
Q2 2026 Ajanta Pharma Ltd Earnings Call Transcript
Ajanta Pharma Transcript: Q2 25/26
Revenue and profit grew 14% and 12% year-over-year, with robust performance across India, U.S., and Africa. EBITDA margin guidance remains at 27% ±1%, supported by strategic investments and improved working capital efficiency.